Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.
Also called NCT06017609
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 314 participants
- Sponsor
- Shionogi Inc.
- Registry
-
NCT06017609
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Bulgaria, Czechia, Poland, Romania, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06017609. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-20 (actual); primary completion 2026-05-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
- Acronym
- POWER-HF
- Condition
- Chronic Heart Failure
- Intervention (Drug)
- JTT-861 Capsules
- Intervention (Drug)
- Placebo Capsules
- Lead sponsor
- Shionogi Inc.
- Collaborator
- ICON Clinical Research
Record details
- Record id
cardio:ct-nct06017609- Content hash
ad432f8f0e685406fd14fb963d79994dec23e13e66d20d9dfe2831a9bd7c6c58